Department of Medicine, University Health Network and Mount Sinai Hospital, Toronto, Canada; Department of Medicine, University of Toronto, Toronto, Canada.
Public Health Research Institute, Rutgers, The State University of New Jersey, Newark, NJ, USA.
Respir Med. 2018 Dec;145:80-88. doi: 10.1016/j.rmed.2018.10.022. Epub 2018 Oct 22.
The risk of all-cause mortality of nontuberculous mycobacterial lung disease (NTMLD) in the United States (US) population is not well established.
This study aims to assess the public health burden of NTMLD in the US by comparing the relative risk of all-cause mortality in the NTMLD population with an age- and sex-matched cohort from the general population.
Patients with physician claims for NTMLD (ICD-9 0.031; ICD-10 A31.0) were identified between 2007 and 2016 from a large US national managed care insurance plan covering approximately 15-18 million members annually. A control group with no NTMLD ICD-9 or 10 codes was randomly selected from the general population and matched 3:1 to the NTMLD sample according to birth year, gender, and insurance benefit coverage. The date of first NTMLD diagnosis of each patient was assigned to the matched controls as the index date. The Cox proportional hazard method compared survival between cohorts, adjusting for demographic factors and baseline comorbidities.
A total of 2005 patients with NTMLD and 6014 controls were identified, with a mean follow-up duration of 3.4 years and 3.7 years, respectively. The NTMLD group had substantially higher proportions of patients with asthma (23.3% versus 3.5%), bronchiectasis (36.5% versus 0.1%), COPD (52.0% versus 5.9%), arrhythmia (22.6% versus 6.5%), coronary artery disease (18.5% versus 6.6%), heart failure (11.9% versus 4.1%), and cancer (18.5% versus 5.0%). The unadjusted rate of all-cause mortality from the index date was 20.7 per 1000 person-years in the NTMLD group vs 5.6 per 1000 person-years in the control group (rate ratio = 3.73; 95% CI: 2.93-4.75). Multivariable Cox regression, adjusted for the above variables as well as all other important baseline covariates, showed a doubling risk of all-cause mortality (hazard ratio [HR] = 2.06; CI: 1.52-2.79; P < 0.001) in the NTMLD vs control group.
All-cause mortality, adjusted for other factors, more than doubled with NTMLD compared with an age-sex-matched control group in a large US national managed care insurance plan.
美国(US)人群中非结核分枝杆菌肺病(NTMLD)的全因死亡率风险尚不清楚。
本研究旨在通过比较 NTMLD 人群与一般人群中年龄和性别匹配队列的全因死亡率的相对风险,评估 NTMLD 在 US 人群中的公共卫生负担。
从一家大型美国国家管理式医疗保险公司中确定了 2007 年至 2016 年间有医生声称患有 NTMLD(ICD-9 0.031;ICD-10 A31.0)的患者。从一般人群中随机选择一个没有 NTMLD ICD-9 或 10 代码的对照组,并根据出生年份、性别和保险福利覆盖范围以 3:1 的比例与 NTMLD 样本相匹配。每位患者的首次 NTMLD 诊断日期被分配给匹配的对照组作为索引日期。Cox 比例风险法比较了队列之间的生存情况,同时调整了人口统计学因素和基线合并症。
共确定了 2005 例 NTMLD 患者和 6014 例对照组患者,平均随访时间分别为 3.4 年和 3.7 年。NTMLD 组患者中哮喘(23.3%比 3.5%)、支气管扩张症(36.5%比 0.1%)、COPD(52.0%比 5.9%)、心律失常(22.6%比 6.5%)、冠状动脉疾病(18.5%比 6.6%)、心力衰竭(11.9%比 4.1%)和癌症(18.5%比 5.0%)的比例显著更高。在索引日期,NTMLD 组的全因死亡率为 20.7/1000 人年,对照组为 5.6/1000 人年(比率比[RR]为 3.73;95%CI:2.93-4.75)。多变量 Cox 回归分析调整了上述变量以及所有其他重要的基线协变量后,显示 NTMLD 组的全因死亡率风险增加了一倍(危险比[HR]为 2.06;CI:1.52-2.79;P<0.001)。
在一项大型美国国家管理式医疗保险公司中,与年龄和性别匹配的对照组相比,调整其他因素后,NTMLD 患者的全因死亡率增加了一倍以上。